Search results for "Recurrence"

showing 10 items of 1036 documents

Minilaparoscopic aortic lymphadenectomy.

2015

Abstract Study Objective To show the feasibility of performing aortic lymphadenectomy with 3-mm instruments in gynecologic malignancies. Patient A 43-year-old, multiparous patient with serous ovarian cancer grading 2, Federation Internationale de Gynecologie et d'Obstetrique stage IC (intraoperative spillage). Intervention The patient was accidentally diagnosed with ovarian cancer after a right adnexectomy performed for an ovarian cyst. Once referred to our center, a delayed surgical staging was planned including total hysterectomy, left adnexectomy, aortic and pelvic lymphadenectomy, peritoneal biopsies, and total omentectomy. Minilaparoscopy was believed to be feasible to achieve it. Meas…

Adultmedicine.medical_specialtymedicine.medical_treatmentOperative TimeSerous ovarian cancermedicineHumansGynecologic cancerGrading (tumors)AortaOvarian NeoplasmsHysterectomyOvarian cystbusiness.industryOvarian NeoplasmMedicine (all)Lymph NodeObstetrics and GynecologyPostoperative complicationmedicine.diseaseSurgeryminilaparoscopicMinilaparoscopyFeasibility StudieSettore MED/40 - GINECOLOGIA E OSTETRICIATreatment OutcomeChemotherapy AdjuvantOperative timeFeasibility StudiesLymph Node ExcisionLymphadenectomyFemaleLaparoscopyLymph NodesNeoplasm Recurrence LocalOvarian cancerbusinessaortic lymphadenectomyHumanJournal of minimally invasive gynecology
researchProduct

Prospective randomized comparison of conventional instruments and the Harmonic Focus(®) device in breast-conserving therapy for primary breast cancer.

2011

Abstract Background In recent years, surgeons have utilized Harmonic instruments to perform breast cancer resection. Retrospective and prospective studies have demonstrated that the use of this surgical device for mastectomy and axillary dissection can reduce perioperative blood loss, seroma formation, and duration and total amount of drainage. No study has analyzed the feasibility of Harmonic instruments in breast-conserving surgery. We conducted a prospective, randomized clinical trial comparing Harmonic instrument and conventional surgery in the performance of breast-conserving surgery and axillary procedures to determine differences in surgical procedures, postoperative outcome, and com…

Adultmedicine.medical_specialtymedicine.medical_treatmentUltrasonic TherapyBreast NeoplasmsMastectomy SegmentalRisk AssessmentStatistics Nonparametriclaw.inventionBreast cancerPostoperative ComplicationsRandomized controlled triallawGermanymedicineBreast-conserving surgeryHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingPostoperative CareAcademic Medical CentersChi-Square Distributionbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSurgical InstrumentsSurvival AnalysisSurgeryLogistic ModelsSeromaTreatment OutcomeOncologySeromaMultivariate AnalysisSurgeryFemaleNeoplasm Recurrence LocalComplicationbusinessChi-squared distributionMastectomyFollow-Up StudiesEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Endoscopic treatment of recurrent sigmoid volvulus with colopexy assisted by T-fasteners and colostomy.

2016

Aged 80 and overMalemedicine.medical_specialtySigmoid Diseasesmedicine.diagnostic_testbusiness.industryGeneral surgerymedicine.medical_treatmentGastroenterologyColostomyT fastenersEndoscopy GastrointestinalEndoscopy03 medical and health sciences0302 clinical medicineRecurrence030220 oncology & carcinogenesisColostomyMedicineHumans030211 gastroenterology & hepatologySigmoid volvulusbusinessEndoscopic treatmentIntestinal VolvulusEndoscopy
researchProduct

Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

2007

Liver or lung metastases usually relapse under chemotherapy. Such life-threatening condition urgently needs new, systemic anticancer compounds, with original and efficient mechanisms of action. In B16 melanoma mice treated with cyclophosphamide, D'Agostini et al. [D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., Garaci, E., 2005. Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205-1212.] recently found that OM-174, a chemically defined Toll-like receptor(TLR)2/4 agonist, reduces tumor progression and prolongs survival. Here we review 149 articles concerning molecular mechanisms of TLR2…

AgonistLipopolysaccharidesCyclophosphamidemedicine.drug_classmedicine.medical_treatmentNitric Oxide Synthase Type IIAntineoplastic AgentsApoptosisNitric oxidechemistry.chemical_compoundRecurrenceNeoplasmsMedicineAnimalsHumansPharmacologyChemotherapybusiness.industryTumor Necrosis Factor-alphaCancerDendritic Cellsmedicine.diseaseNeoadjuvant TherapyToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4TLR2Lipid ATreatment OutcomechemistryTumor progressionChemotherapy AdjuvantDrug Resistance NeoplasmEnzyme InductionImmunologyCancer researchBCG VaccineTumor necrosis factor alphaImmunotherapybusinessmedicine.drugSignal TransductionT-Lymphocytes CytotoxicEuropean journal of pharmacology
researchProduct

Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma

2018

Objective Ampulla of Vater carcinoma (AVC) has a broad spectrum of different prognoses. As such, new moderators of survival are urgently needed. We aimed at clarifying the prognostic role of perineural invasion in AVC. Methods Using PubMed and SCOPUS databases, we conducted the first systematic review and meta-analysis on this topic. Results Analyzing 29 articles for a total of 2379 patients, we found that the presence of perineural invasion increased the risk of all-cause mortality more than 2 times (relative risk [RR], 2.07; 95% confidence interval [CI], 1.78-2.42 [P < 0.0001]; hazard ratio [HR], 2.72; 95% CI, 1.86-3.97 [P < 0.0001]), of cancer-specific mortality more than 6 times (…

Ampulla of Vatermedicine.medical_specialtyEndocrinology Diabetes and MetabolismPNIPerineural invasionPerineumGastroenterology03 medical and health sciencesBroad spectrum0302 clinical medicineEndocrinologypapilla PNI perineural VaterRisk FactorsInternal medicineInternal MedicinemedicineCarcinomaHumansNeoplasm InvasivenessVaterpapillaHepatologybusiness.industryHazard ratioAmpulla of VaterPrognosismedicine.diseaseConfidence intervalPancreatic Neoplasmsmedicine.anatomical_structure030220 oncology & carcinogenesisRelative riskMeta-analysisperineural030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessCarcinoma Pancreatic DuctalPancreas
researchProduct

Anal canal mixed adenoneuroendocrine carcinoma in a young patient misdiagnosed as anal abscess.

2021

Mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) are rare tumours of gastrointestinal tract, extremely rare in anal canal. We report a case of misdiagnosed MiNEN in a 38-year-old woman initially conservatively treated for a supposed anal fistula. In a second proctological evaluation, biopsy of the anal neoformation was performed and the histological specimen diagnosed a MiNEN. The complete staging showed a disseminate disease and the patient started a chemotherapy schedule. After 6 months, stable disease was revealed at the last imaging performed and radical surgery was offered to the patient that is actually on oncological follow-up without recurrence at 1 year.

Anal fistulaAdultmedicine.medical_specialtymedicine.diagnostic_testColorectal cancerbusiness.industryAnal CanalGeneral MedicineAnal canalmedicine.diseaseAbscessAnal Canal Mixed Adenoneuroendocrine CarcinomaCarcinoma Neuroendocrinemedicine.anatomical_structureSurgical oncologyBiopsymedicineHumansFemaleRadiologyRadical surgeryDiagnostic ErrorsNeoplasm Recurrence LocalbusinessAbscessBMJ case reports
researchProduct

Outcomes of aortic valve repair according to valve morphology and surgical techniques

2012

OBJECTIVES: The aim of this study was to assess the impact of aortic valve morphology and different surgical aortic valve repair techni- ques on long-term clinical outcomes. METHODS: Between February 2003 and May 2010, 216 patients with aortic insufficiency underwent aortic valve repair in our institu- tion. Ages ranged between 26 and 82 years (mean 53 ± 15 years). Aortic valve dysfunctions, according to functional classification, were: type I in 55 patients (25.5%), type II in 126 (58.3%) and type III in 35 (16.2%). Sixty-six patients (27.7%) had a bicuspid valve. Aortic valve repair techniques included sub-commissural plasty in 138 patients, plication in 84, free-edge reinforcement in 80,…

Aortic valveMaleTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateAortic valve repairRecurrenceRisk FactorsMitral valve80 and overHospital MortalityCoronary Artery BypassAortaUltrasonographyAged 80 and overTricuspid valveCalcinosisCardiac Valve AnnuloplastyMiddle AgedAortic valve repair • Bicuspid aortic valve • Tricuspid aortic valve • Aortic annulus stabilization medicine.anatomical_structureTreatment OutcomeAortic ValveReplantationcardiovascular systemCardiologyChordae TendineaeMitral ValveFemaleChordae tendineaeCardiology and Cardiovascular MedicineAdult; Aged; Aged 80 and over; Aorta; Aortic Valve; Aortic Valve Insufficiency; Blood Vessel Prosthesis Implantation; Calcinosis; Chordae Tendineae; Coronary Artery Bypass; Disease-Free Survival; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitral Valve; Proportional Hazards Models; Recurrence; Replantation; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography; Cardiac Valve Annuloplasty; Suture TechniquesPulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAortic Valve InsufficiencyRisk AssessmentCardiac Valve AnnuloplastyDisease-Free SurvivalBlood Vessel Prosthesis ImplantationBicuspid valveInternal medicinemedicineHumansAgedProportional Hazards ModelsMitral valve repairbusiness.industrySuture TechniquesSettore MED/23 - Chirurgia CardiacaOriginal ArticlesSurgerySurgerybusiness
researchProduct

High-frequency rotational ablation following failed percutaneous transluminal coronary angioplasty.

1994

Percutaneous transluminal coronary angioplasty (PTCA) failed in 29 of 1,150 patients (2.5%) after successful passage of the guide wire. The reasons for failure were inability to pass the lesion with a balloon in 28 patients and inability to dilate the lesion in 1 patient. In these patients (15 stenoses and 14 chronic occlusions) rotational ablation was performed. We were able to pass the burr through the lesion in all of them, resulting in a reduction of diameter stenosis from 87 +/- 15 to 51 +/- 18%. Rotational ablation alone was initially successful (stenoses reduction > 20% and residual stenoses < 50%) in 15 of 29 (52%) patients. Additional PTCA was performed in 21 of 29 (72%) patients, …

Atherectomy CoronaryMalemedicine.medical_specialtyPercutaneous transluminal coronary angioplastyRotational ablationCoronary Artery DiseaseBalloonCoronary AngiographyLesionRecurrenceInternal medicinemedicineHumansMajor complicationTreatment FailureAngioplasty Balloon Coronarybusiness.industryMiddle AgedCoronary heart diseaseSurgeryDiameter stenosisCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessCatheterization and cardiovascular diagnosis
researchProduct

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct

PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer

2020

68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of this study is to determine the optimum time for performing these PET/CT scans in a large cohort of patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve (ROC) generated by plottin…

Biochemical recurrenceCancer Researchmedicine.medical_treatment68Gallium-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicine<sup>68</sup>gallium-psma pet/ctprostate-specific-antigenPSA kinetics thresholdsbiochemical recurrenceMedicineoptimal cutoff levelPET-CTPsa kineticsbusiness.industryProstatectomylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensprostate cancermedicine.diseaseRadiation therapyProstate-specific antigenOncology030220 oncology & carcinogenesisRecurrent prostate cancerbusinessNuclear medicineCancers
researchProduct